Hyperthermia

Hyperthermia is a condition characterized by an abnormally high body temperature due to failed thermoregulation. It can result from environmental exposure, physiological stress, or genetic susceptibility. Prompt recognition and management are crucial to prevent severe complications and organ damage.

Definition and Classification

Definition of Hyperthermia

Hyperthermia is defined as an elevation of core body temperature above the normal range of 36.5-37.5°C, caused by the body’s inability to dissipate heat adequately or excessive heat production. Unlike fever, hyperthermia is not mediated by pyrogens or hypothalamic set point changes.

Types of Hyperthermia

• Heat cramps: Painful, involuntary muscle contractions typically occurring during intense physical activity in hot environments.
• Heat exhaustion: Characterized by fatigue, weakness, dizziness, nausea, and profuse sweating due to prolonged heat exposure and dehydration.
• Heat stroke: A life-threatening condition with core temperature exceeding 40°C, often accompanied by central nervous system dysfunction, altered mental status, and organ failure.
• Malignant hyperthermia: A rare genetic disorder triggered by certain anesthetic agents, leading to uncontrolled skeletal muscle metabolism and rapid rise in body temperature.
• Drug-induced hyperthermia: Caused by stimulants or medications that interfere with thermoregulatory processes.
• Neuroleptic malignant syndrome: Severe reaction to antipsychotic drugs presenting with hyperthermia, muscle rigidity, and autonomic instability.

Etiology

Environmental Factors

• High ambient temperature during summer or in poorly ventilated environments.
• High humidity impairing evaporative cooling through sweating.
• Excessive sun exposure leading to increased heat absorption.

Physiological and Individual Factors

• Extremes of age, with infants and elderly being more susceptible.
• Dehydration reducing heat dissipation through sweat and circulation.
• Obesity, which increases insulation and limits heat loss.
• Pre-existing medical conditions, including cardiovascular, endocrine, or neurological disorders.

Pharmacological Causes

• Medications such as anticholinergics and stimulants that interfere with normal thermoregulation.
• Illicit drugs including cocaine, amphetamines, and MDMA, which increase metabolic heat production.
• Anesthetic agents capable of triggering malignant hyperthermia in genetically susceptible individuals.

Pathophysiology

Normal Thermoregulation

The human body maintains a stable core temperature through complex mechanisms controlled by the hypothalamus. Heat is produced primarily by metabolism in muscles and organs and is dissipated through radiation, conduction, convection, and evaporation. Sweating and vasodilation of cutaneous blood vessels are key processes that promote heat loss.

Mechanisms Leading to Hyperthermia

• Excessive heat production: Increased metabolic activity during exercise, fever-independent metabolic disorders, or drug-induced stimulation can overwhelm the body’s cooling capacity.
• Impaired heat dissipation: High environmental temperature, humidity, or clothing that restricts airflow reduces evaporative and convective heat loss.
• Cellular and systemic effects: Elevated temperature disrupts protein structures, enzyme activity, and membrane integrity, leading to cellular dysfunction and potential multi-organ injury.

Complications at Cellular and Organ Level

• Protein denaturation causing loss of structural and enzymatic functions.
• Enzyme dysfunction affecting metabolic pathways and energy production.
• Multi-organ failure, including renal, hepatic, cardiovascular, and neurological systems, in severe or prolonged hyperthermia.

Clinical Features

• Heat cramps: Localized muscle pain and spasms, typically in the legs or abdomen, associated with heavy sweating.
• Heat exhaustion: Weakness, fatigue, dizziness, headache, nausea, vomiting, and profuse sweating. Skin may be pale and moist, with mild tachycardia.
• Heat stroke: Core temperature above 40°C, altered mental status ranging from confusion to coma, dry or hot skin, hypotension, tachycardia, and potential organ dysfunction.
• Malignant hyperthermia: Rapid increase in body temperature during anesthesia, generalized muscle rigidity, tachycardia, metabolic acidosis, and rhabdomyolysis.
• Neurological manifestations: Confusion, agitation, seizures, and loss of consciousness in severe cases.
• Cardiovascular and renal manifestations: Hypotension, tachyarrhythmias, acute kidney injury due to dehydration or rhabdomyolysis.

Diagnosis

History and Physical Examination

Diagnosis of hyperthermia begins with a thorough history, including recent exposure to heat, physical activity, medication use, and family history of malignant hyperthermia. Physical examination focuses on vital signs, skin condition, level of consciousness, and signs of dehydration or organ dysfunction.

Laboratory Investigations

• Electrolytes and renal function: Assessment of sodium, potassium, creatinine, and blood urea nitrogen to detect dehydration or renal impairment.
• Creatine kinase levels: Elevated levels indicate muscle breakdown, especially in malignant hyperthermia or heat stroke.
• Arterial blood gas analysis: Evaluation for metabolic acidosis or hypoxemia.
• Genetic testing: Identification of susceptibility to malignant hyperthermia in at-risk individuals or families.

Imaging Studies

Imaging is rarely required for hyperthermia itself but may be indicated to evaluate complications or differential diagnoses, such as brain edema or organ injury in severe heat stroke cases.

Management

Initial Emergency Measures

• Cooling techniques: Rapid external cooling using ice packs, cold water immersion, or cooling blankets. Internal cooling may include cooled intravenous fluids or gastric/bladder lavage in severe cases.
• Fluid resuscitation: Intravenous administration of isotonic fluids to correct dehydration and maintain hemodynamic stability.
• Oxygen therapy: Supplemental oxygen to improve tissue oxygenation, especially in patients with altered mental status or cardiovascular compromise.

Specific Treatment by Type

• Heat cramps: Rest, hydration, and electrolyte replacement.
• Heat exhaustion: Rapid cooling, oral or intravenous fluids, and monitoring for progression to heat stroke.
• Heat stroke: Aggressive cooling, intravenous fluids, correction of electrolyte imbalances, and supportive care in an intensive care setting if necessary.
• Malignant hyperthermia: Immediate discontinuation of triggering anesthetic agents, administration of dantrolene, cooling measures, and intensive monitoring of organ function.

Supportive Care

• Continuous monitoring of vital signs and neurological status.
• Correction of electrolyte and acid-base disturbances.
• Renal support including monitoring urine output and preventing acute kidney injury.
• Cardiovascular support for hypotension or arrhythmias if present.

Prevention

• Environmental precautions: Avoid prolonged exposure to high temperatures, ensure adequate ventilation, and take frequent breaks during physical activity in hot conditions.
• Hydration strategies: Maintain sufficient fluid intake before, during, and after heat exposure to prevent dehydration and support thermoregulation.
• Education on early recognition: Training individuals to recognize early signs of heat-related illness, such as muscle cramps, dizziness, and excessive fatigue, to prompt timely intervention.
• Preoperative screening: Assessing patients for genetic susceptibility to malignant hyperthermia before exposure to triggering anesthetic agents.

Prognosis

The outcome of hyperthermia depends on the type, severity, timeliness of intervention, and underlying health status of the patient. Mild forms like heat cramps and heat exhaustion generally have a favorable prognosis with prompt management. Severe cases such as heat stroke and malignant hyperthermia carry a higher risk of complications and mortality if treatment is delayed. Early recognition and aggressive management significantly improve survival rates and reduce long-term organ damage.

References

1. Guyton AC, Hall JE. Textbook of Medical Physiology. 14th ed. Philadelphia: Elsevier; 2021.
2. Katz AM. Physiology of the Heart. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2017.
3. Leon LR, Helwig BG. Heat stroke: Role of the systemic inflammatory response. J Appl Physiol. 2010;109(6):1980-1988.
4. Riazi S, Larach MG. Malignant hyperthermia: A review. Orphanet J Rare Dis. 2020;15:134.
5. Bouchama A, Knochel JP. Heat stroke. N Engl J Med. 2002;346:1978-1988.
6. Roberts WO. Heat illness in athletes. N Engl J Med. 2008;358:2130-2136.
7. Hines RL, Marschall KE. Stoelting’s Pharmacology & Physiology in Anesthetic Practice. 5th ed. Philadelphia: Wolters Kluwer; 2021.
8. Epstein Y, Yanovich R. Heatstroke. N Engl J Med. 2019;380:2449-2459.
9. Malik A, Ahmad A. Drug-induced hyperthermia: Mechanisms and management. Clin Toxicol. 2017;55(7):635-648.
10. Wang R, Liu W. Environmental and occupational hyperthermia: Prevention and management. Curr Opin Pediatr. 2021;33(2):233-240.